[Merc.]

Here is a study that shows that nolva reduces the blood plasma levels of type II AI's..


Interactions of antioestrogens and aromatase inhibitors.

Schmid P, Possinger K

Department of Oncology and Hematology, Charite Campus Mitte, Humboldt University Berlin, Germany.

Aromatase inhibitors and antioestrogens have shown substantial activity in primary and advanced breast cancer. Since they exhibit different modes of action, attempts have been made to combine them or to use them sequentially in order to potentially increase their efficacy. In preclinical studies, combined, sequential or alternating treatments with aromatase inhibitors and antioestrogens have failed to provide higher antitumoural activity. There are relevant pharmacokinetic interactions resulting in decreased plasma concentrations of third generation aromatase inhibitors when combined with tamoxifen. Several randomised clinical trials comparing single agent and combined treatment with tamoxifen and aminoglutethimide failed to show any benefit for the combination. Early results of the adjuvant ATAC trial indicate that single agent anastrozole is superior to tamoxifen or the combination of both. Several trials are ongoing which might help to further define the role of sequential or combined treatment with aromatase inhibitors and antioestrogens. However, to date, looking at the current evidence, combined treatment with aromatase inhibitors and antioestrogens does not appear to provide additional benefit compared to single agent treatment.( End study)....


That study is very interesting... It is also why Anthony Roberts uses aromasin in his pct protocol..

You see aromasin -a type I AI - doesn't need to be present to continue doing its job on the aromatase enzyme ...

A type II AI which is partially eliminated by nolva - and unfortunately needs to be present to continue its aromatase inhibition.. Once a type I AI does its job the enzyme its attached to is useless.. So nolva can reduce the blood plasma levels of letro , adex ( type II ai's)....


Merc.